PepGen Inc
NASDAQ:PEPG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Syngene International Ltd
NSE:SYNGENE
|
IN |
|
E
|
Easy Software AG
XHAM:ESY
|
DE |
|
Sanchuan Wisdom Technology Co Ltd
SZSE:300066
|
CN |
|
V
|
Visa Steel Ltd
NSE:VISASTEEL
|
IN |
PepGen Inc
Accounts Payable
PepGen Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PepGen Inc
NASDAQ:PEPG
|
Accounts Payable
$822k
|
CAGR 3-Years
-16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$34.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$715m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$20.9B
|
CAGR 3-Years
137%
|
CAGR 5-Years
71%
|
CAGR 10-Years
36%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.9B
|
CAGR 3-Years
134%
|
CAGR 5-Years
91%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$6.8B
|
CAGR 3-Years
126%
|
CAGR 5-Years
70%
|
CAGR 10-Years
47%
|
|
PepGen Inc
Glance View
PepGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2022-05-06. PepGen Inc. is a clinical-stage biotechnology company advancing the oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotides (EDOs) are designed to target the underlying causes of rare genetic diseases, such as duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The firm through its enhanced delivery oligonucleotide (EDO) platform developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of DMD patients with mutations amenable to exon 51-skipping approach. The firm is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of DM1.
See Also
What is PepGen Inc's Accounts Payable?
Accounts Payable
822k
USD
Based on the financial report for Dec 31, 2025, PepGen Inc's Accounts Payable amounts to 822k USD.
What is PepGen Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
3%
Over the last year, the Accounts Payable growth was -53%. The average annual Accounts Payable growth rates for PepGen Inc have been -16% over the past three years , 3% over the past five years .
